What ZetrOZ does

ZetrOZ Systems is a privately-held medical device company headquartered in Trumbull, Connecticut that develops and manufactures wearable ultrasound devices for sustained acoustic medicine (sam®) therapy. The company's core technology, OZ Inside™, delivers low-intensity long-duration ultrasound through FDA-cleared wearable patches to treat soft tissue injuries, chronic musculoskeletal pain, and osteoarthritis without surgery or pharmaceuticals. Its product portfolio includes sam® Sport (introduced 2013), sam® 2.0 (2019), sam® X1 (2022), and the newly launched sam® 3.0 (June 2026), supported by advanced 3M hypoallergenic coupling patches.

The company generates revenue primarily through prescription-based hardware sales in the US (distributed via physicians and physical therapists) and direct-to-consumer e-commerce platforms (samrecover.com, samsport.com) in international markets including Canada, the EU, UAE, Malaysia, and Singapore. Its customer base spans professional sports organizations (MLB, NBA, NFL), Olympic and collegiate athletes, US military veterans (under a VA contract), geriatric arthritis patients, orthopaedic surgeons, and frontline workers. The company operates four cGMP and ISO 13485 certified US manufacturing facilities and holds 46-48 global patents.

ZetrOZ is led by founder George K. Lewis, PhD (President & CEO), with JoAnne Guarino as COO, Sabrina Lewis as Director of Regulatory Affairs, and Robert Butler as Controller. The company has received substantial non-dilutive funding from NIH, DOD, NASA, NSF, and Connecticut state government, and has raised venture capital from Connecticut Innovations, Maine Angels, Horizon Technology Finance, and Fort Point Angels. Clinical validation includes 42+ peer-reviewed publications and 20+ clinical studies supporting outcomes such as over 50% faster soft tissue healing, up to 52% pain reduction in osteoarthritis, and over $27,000 in medical cost savings per patient when treatment is introduced early.

Name

ZetrOZ

Legal name

ZetrOZ Systems, LLC

Website

https://zetroz.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

ZetrOZ Systems is a privately-held US medical device company that develops and manufactures FDA-cleared wearable ultrasound devices (sam®) for non-invasive treatment of soft tissue injuries, chronic musculoskeletal pain, and osteoarthritis, serving athletes, military veterans, geriatric patients, and healthcare providers.

Ownership category

akta.pro rank

Product category

Wearable Therapeutic Ultrasound Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Ultrasound & Echography Systems (HLAHABAD)

Keywords

• Wearable ultrasound devices
• Sustained acoustic medicine
• Soft tissue healing
• Chronic pain management
• FDA-cleared medical devices

Headquarters

HQ city

Trumbull

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Wearable Ultrasound Device Sales: Sale of sam® product line devices (sam Sport, sam 2.0, sam X1, sam 3.0) as prescription medical devices for at-home use. Revenue from direct hardware sales through company e-commerce platforms and potentially through healthcare provider prescriptions.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Core offering

ZetrOZ Systems develops, manufactures, and sells FDA-cleared wearable ultrasound medical devices under the sam® (Sustained Acoustic Medicine) brand that deliver non-invasive, multi-hour continuous low-intensity ultrasound therapy to accelerate soft-tissue healing and relieve chronic musculoskeletal pain. The company's flagship offerings — sam Sport, sam 2.0, sam X1, and sam 3.0 — are sold through prescription channels, direct e-commerce, and enterprise contracts to professional sports teams and government healthcare programs.

Product overview

ZetrOZ Systems offers a portfolio of wearable sustained acoustic medicine (sam) devices for non-invasive treatment of soft-tissue injuries and musculoskeletal conditions. The product line includes: sam Sport (first generation, introduced 2013), sam 2.0 (second generation with improved performance), sam X1 (wireless prescription model), and sam 3.0 (latest generation with extended battery life and dual treatment zones). The devices deliver continuous low-intensity ultrasound therapy through proprietary OZ Inside technology, with supporting sam Advanced Coupling Patches for daily use. All devices are FDA-cleared for daily home use and are supported by clinical research including 42 peer-reviewed publications.

Differentiator

Problem solved

Functional benefit

Brands

• sam®: Sustained Acoustic Medicine product line for wearable ultrasound therapy devices for treating soft-tissue injuries and chronic musculoskeletal conditions
• sam® Sport
• sam® 2.0
• sam® X1
• sam® 3.0
• OZ Inside™
• samrecover.com
• samsport.com

Products and services

• sam 3.0 Latest generation FDA-cleared wearable ultrasound device delivering sustained acoustic medicine for treating soft-tissue injuries, offering up to 8 hours of continuous battery life, 4-amp fast charging via medical-grade USB-C, improved temperature regulation, and dual independently operated treatment zones for athletes, military personnel, frontline workers, and geriatric patients.
• sam 2.0 Advanced wearable sustained acoustic medicine device FDA-cleared as the only long-duration ultrasound device cleared for daily home use, featuring up to 4x faster rapid charging, improved ergonomics, military-medical-grade housing, data capture and treatment history monitoring, and 3M hypoallergenic patches with patented gel-capture seals.
• sam Sport First FDA-cleared wearable device for multi-hour continuous ultrasound therapy introduced in 2013, delivering ultrasonic waves that penetrate 5 cm into tissue to increase circulation, oxygen and nutrient delivery, and remove waste products from musculoskeletal injury sites for professional and collegiate athletes.
• sam X1 Wireless ultrasound device for at-home use, the first innovative wireless FDA-cleared device for this application, featuring hypoallergenic 3M patches, smart treatment monitoring, key-lock feature, and gel-capture patches, and available by prescription in the U.S.

Quantifiable outcome

• Over 50% faster healing of soft tissue injuries compared to standard of care
• +4 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Arthritis FoundationcoreGTM or Marketing PartnerPremier sponsor of Arthritis Foundation's 2026 Pathways Conference; received Ease of Use Certification for sam 2.0; deepening partnership to educate patients on drug-free treatment options for knee osteoarthritis; member of OA Action Alliance coalition led by Arthritis Foundation and CDC
• American Academy of Orthopaedic Surgeons (AAOS)coreGTM or Marketing PartnerShowcased sam sustained acoustic medicine technology at AAOS annual meeting in New Orleans (March 3-5) as part of efforts to expand adoption among orthopaedic surgeons across the United States
• Professional Baseball Athletic Trainers Society (PBATS)coreGTM or Marketing PartnerPartnership to educate professional baseball teams on sam technology; company attends MLB spring training camps to present technology for athlete recovery
• USA Field HockeycoreStrategic or Co-development PartnerMajor Sports Medicine Partnership for promoting sustained acoustic medicine technology in athletic recovery programs
• National Basketball Trainers Association (NBATA)coreStrategic or Co-development PartnerMajor Sports Medicine Partnership supporting athletic trainers and player recovery
• National Institutes of Health (NIH)coreStrategic or Co-development PartnerResearch funding from NIH and National Institute of Minority Health and Health Disparities for arthritis treatment development; NIH Phase II SBIR grant for next generation sam technology
• U.S. Department of Defense (DOD)coreStrategic or Co-development PartnerUSAMMA Phase II contract to accelerate healing of soft tissue injuries; research shows over 50% improvement vs standard of care
• NASA / National Space Biomedical Research InstitutecoreStrategic or Co-development PartnerNSBRI Award and SBIR/STTR Grant for space technology development; research on wearable ultrasound for astronauts and space applications
• University of Miami Sports Medicine InstitutecoreStrategic or Co-development PartnerDr. Thomas Best serves as team physician and research director; NIH-funded laboratory for muscle inflammation and repair research
• Brigham Young University - Dept of Exercise SciencesminorStrategic or Co-development PartnerDr. David Draper leads research and clinical education; 114 publications in scholarly journals; co-author of leading therapeutic modalities textbook
• American Sports Medicine Institute (Dr. Kevin Wilk)minorStrategic or Co-development PartnerRehabilitation consultant for Tampa Bay Rays; 155+ journal articles on sports injury rehabilitation
• OurSeniors.net MagazineminorGTM or Marketing PartnerDesignated as Approved Vendor for senior healthcare audience; reaching geriatric patient demographic
• Global Knee SummitminorGTM or Marketing PartnerParticipated in Global Knee Summit in Dubai (January 2026) delivering educational talks on sam technology
• National Orthopedic FoundationminorStrategic or Co-development PartnerPartnership for 2022 supporting research and development of innovative treatments in mechanobiology

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Zynex Medical: Zynex markets non-opioid pain management devices (TENS, NMES, monitoring) prescribed by physicians and PTs. Comparable to ZetrOZ in the prescription-based, non-opioid pain management category and similar physician-channel GTM motion, although Zynex uses electrical rather than ultrasound energy.
• BTL Group: BTL develops non-invasive therapeutic devices for musculoskeletal pain and rehabilitation, including EMTT (extracorporeal magnetotransduction therapy) and shockwave systems. Comparable to ZetrOZ as a non-pharmaceutical, device-based pain management company serving orthopaedic and physical therapy channels.
• Misonix (Bioventus): Misonix (now part of Bioventus) manufactures therapeutic and surgical ultrasound systems used in wound healing and tissue repair. Most directly comparable to ZetrOZ as another ultrasound-based therapeutic medical device company targeting soft-tissue recovery.
• BioElectronics Corporation: BioElectronics makes wearable, drug-free medical devices (e.g., ActiPatch) for chronic and post-surgical pain relief. Closely comparable to ZetrOZ in delivery mechanism (wearable OTC/prescription device), target indications (soft-tissue pain), and consumer/healthcare dual channel.

Broad incumbents

• Stryker Corporation: Stryker is a major orthopaedic and medical-surgical company whose Sports Medicine and Orthopaedics divisions overlap with ZetrOZ's athlete and orthopaedic surgeon customer base. Comparable as a broad incumbent with adjacent sports-medicine devices and similar end customers, though Stryker's portfolio is much wider and primarily surgical/implantable.
• Medtronic (Pain Therapies): Medtronic's Pain Therapies franchise (intrathecal drug delivery, spinal cord stimulation) is one of the largest non-opioid chronic pain platforms. Comparable to ZetrOZ in addressing chronic musculoskeletal pain as an alternative to opioid/surgical intervention, though Medtronic serves it via implanted devices in a much broader portfolio.
• Abbott (Neuromodulation): Abbott's Neuromodulation business (Proclaim DRG, dorsal root ganglion stimulation) targets chronic pain and is a broader incumbent in non-opioid pain management. Comparable to ZetrOZ as an alternative-to-medication chronic pain therapy, though Abbott operates at far greater scale and via implantable rather than wearable delivery.
• DJO / Enovis: Enovis (formerly DJO) is a large orthopaedic and recovery sciences company offering bracing, pain management, and rehabilitation products used by surgeons, PTs, and athletic trainers. Comparable to ZetrOZ in serving orthopaedic surgeons and physical therapy channels with non-invasive musculoskeletal therapies, though at much broader scale.

Emerging players

• Soliton: Soliton is developing Rapid Acoustic Pulse (RAP) technology for therapeutic and aesthetic indications. Comparable to ZetrOZ as an emerging player using acoustic energy in a medical device format, though Soliton has historically focused on aesthetic tattoo removal rather than musculoskeletal pain.
• Ivivi Health Sciences (now Endonovo Therapeutics): Endonovo (formerly Ivivi) markets pulsed electromagnetic field (PEMF) therapy devices for pain and soft-tissue conditions. Comparable to ZetrOZ as a smaller non-invasive, non-pharmaceutical medical device company competing in the same chronic pain and recovery category through different energy modality.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/sam_recover
• Instagraminstagram.com/sam.recover
• Facebookfacebook.com/ZetrOZSystems
• LinkedInlinkedin.com/company/zetroz-llc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds11 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZetrOZ